OR WAIT null SECS
Click here to read the articles and download the PDF
Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.
A crash course on the bubble itself, including therapeutic areas most affected.
Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.
July 02, 2024
A cross-sectional study evaluates the difference in clinical outcomes and demographics between pediatric RSV patients during these multiple timeframes.
The CRDMO will contribute cell discovery services that will benefit clinical development of novel technologies.
The latest news for pharma industry insiders.
July 01, 2024
Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform.
The company’s latest investment—featuring new cGMP suites at its Devens, MA plant—is valued at $30 million.
June 28, 2024
The North Carolina project adds 1.4 million square feet of dedicated production space for aseptic manufacturing and finished production processes.
A cross-sectional audit study determines how racial and ethnic disparities—among English, Mandarin, and Spanish-speaking patients—can impact access.
June 27, 2024
The deal offers member pharmacies two pricing options, which will take effect Aug. 1.